Atia Vision, which is developing of a modular presbyopia-correcting accommodating IOL, announced the closing of its second tranche of a Series D $20M financing. The financing will be used to continue early clinical experience treating cataract patients and support expansion of Atia Vision’s facility.
“We are pleased to have early clinical evidence demonstrating accommodation, the ability of the eye to change its focus between distant and near objects,” Mariam Maghribi, President and CEO of Atia Vision, said in a company news release. “The team is leveraging valuable learnings from our initial clinical work and incorporating feedback to quickly iterate and implement meaningful product improvements. We look forward to continuing our clinical efforts, including additional clinical sites, and expanding our production capabilities in the coming months.”
Atia Vision’s innovation addresses the unmet needs of cataract and presbyopia patients through a familiar conventional cataract procedure. The Atia Vision modular IOL technology features an accommodating base responsive to the ciliary muscles, simulating the natural mechanism of the eye and fixed lens element that allows for subsequent refractive correction.
The financing was led by Cormorant Asset Management, with participation by The Capital Partnership (TCP), AMED Ventures and Shangbay Capital.